Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases

American Journal of Hypertension

Volumn 15, Issue 12, 2002, Pages 1057-1063

  Franscini, Lorenzo M D ^a,b   Von Vigier, Rodo O ^a   Pfister, Roger ^a   Casaulta Aebischer, Carmen ^a   Fossali, Emilio ^b   Bianchetti, Mario G ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Childhood; Chronic kidney disease; Hypertension; Irbesartan; Proteinuria

Indexed keywords

IRBESARTAN; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; BIPHENYL DERIVATIVE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; TETRAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ALBUMIN BLOOD LEVEL; ARTERIAL PRESSURE; ARTICLE; CHILD; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; MALE; MYALGIA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; RASH; SODIUM BLOOD LEVEL; VERTIGO; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; DRUG ANTAGONISM; DRUG INTERACTION; EVALUATION; PRESCHOOL CHILD; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; STATISTICAL MODEL; TREATMENT OUTCOME;

ADOLESCENT; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DRUG INTERACTIONS; FEMALE; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; MALE; PROSPECTIVE STUDIES; PROTEINURIA; RECEPTORS, ANGIOTENSIN; RENAL DIALYSIS; TETRAZOLES; TREATMENT OUTCOME;

EID: 0036892741     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(02)03083-2     Document Type: Article

References (21)

1. Burnier M, Brunner HR: Angiotensin II receptor antagonists. Lancet 2000;355:637-645.
2. Waeber B: A review of irbesartan in antihypertensive therapy: Comparison with other antihypertensive agents. Curr Ther Res Clin Exp 2001;62:505-523.
3. Perico N, Remuzzi A, Sangalli F, Azzollini N, Mister M, Ruggenenti P, Remuzzi G: The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. J Am Soc Nephrol 1998;9:2308-2317.
4. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878.
5. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
6. Flynn JT: Pharmacologic management of childhood hypertension: Current status, future challenges. Am J Hypertens 2002;15(Suppl): 30S-33S.
7. Schwartz GJ, Haycock GB, Spitzer A: Plasma creatinine and urea concentration in children: Normal values for age and sex. J Pediatr 1976;88:828-830.
8. Vogt BA: Hypertension in children and adolescents: Definition, pathophysiology, risk factors, and long-term sequelae. Curr Ther Res Clin Exp 2001;62:283-297.
9. von Vigier RO, Zberg PM, Teuffel O, Bianchetti MG: Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease. Eur J Pediatr 2000;159:590-593.
10. Haycock GB, Schwartz GJ, Wisotsky DH: Geometric method for measuring body surface area: A height-weight formula validated in infants, children, and adults. J Pediatr 1978;93:62-66.
11. Waeber B, Burnier M, Brunner HR: How to improve adherence with prescribed treatment in hypertensive patients? J Cardiovasc Pharmacol 2000;35(Suppl 3):S23-S26.
12. Hebert LA, Wilmer WA, Falkenhain ME, Ladson-Wofford SE, Nahman NS Jr, Rovin BH: Renoprotection: One or many therapies? Kidney Int 2001;59:1211-1226.
13. Mackay FJ, Pearce GL, Mann RD: Cough and angiotensin II receptor antagonists: Cause or confounding? Br J Clin Pharmacol 1999;47:111-114.
14. Bianchetti MG, Caflisch M, Oetliker OH: Cough and converting enzyme inhibitors. Eur J Pediatr 1992;151:225-226.
15. Hostetter TH: Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 2001;345:910-912.
16. Marino MR, Vachharajani NN: Drug interactions with irbesartan. Clin Pharmacokinet 2001;40:605-614.
17. Sakarcan A, Tenney F, Wilson JT, Stewart JJ, Adcock KG, Wells TG, Vachharajani NN, Hadjilambris OW, Slugg P, Ford NF, Marino MR: The pharmacokinetics of irbesartan in hypertensive children and adolescents. J Clin Pharmacol 2001;41:742-749.
18. Kaplan NM: Angiotensin II-receptor blockers: Will they replace angiotensin-converting enzyme inhibitors in the treatment of hypertension? J Hum Hypertens 2000;14(Suppl 1):S87-S90.
19. 1 receptor antagonists - Beyond the haemodynamic effect. Nephrol Dial Transplant 2000;15:561-565.
20. Guidelines Subcommittee: 1999 World Health Organization - International Society of hypertension guidelines for the management of hypertension. Guidelines Sub-Committee. Blood Press 1999;1 (Suppl):9-43.
21. Jafar TH, Pereira BJG: A cautionary note for nephrologists: Is it time to abandon the use of dihydropyridine calcium channel blockers? Semin Dial 1999;12:137-139.